Marcos Milla, PhD

Chairman of the Board and Interim CSO

Dr. Marcos Milla is a Venture Partner at Samsara BioCapital. Previously, Marcos was the Chief Scientific Officer of Synthorx. At Synthorx, he directed the company's research efforts to discover and develop optimized biologics for oncology and helped lead the company through its IPO and $2.5B acquisition by Sanofi. Prior to Synthorx, Marcos held industry and faculty appointments at GlaxoSmithKline, Perelman School of Medicine at the University of Pennsylvania, Roche Palo Alto, Janssen Research & Development, and Adaptive Biotechnologies.

His drug discovery experience spans multiple therapeutic areas, including oncology, immunology, and neuroscience. He has broad expertise across different research areas and has previously directed efforts on multiple intracellular and extracellular target classes.

Marcos holds a BS in Cell Biology from Universidad Peruana Cayetano Heredia and a PhD in Cell and Molecular Biology from Saint Louis University. He did his postdoctoral training at MIT and Duke University School of Medicine. He also holds an Adjunct Faculty appointment at the Skaags School of Pharmacy and Pharmaceutical Sciences of UCSD.